Migalastat (Galafold) (Amicus therapeutics)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of migalastat 123 mg capsule (equivalent to 150 mg migalastat hydrochloride [HCl]) for long-term treatment of adults with a confirmed diagnosis of Fabry disease (FD) (deficiency of alpha-Gal A) and...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
2018, February 2018
|
| Series: | CADTH common drug review clinical review report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of migalastat 123 mg capsule (equivalent to 150 mg migalastat hydrochloride [HCl]) for long-term treatment of adults with a confirmed diagnosis of Fabry disease (FD) (deficiency of alpha-Gal A) and who have an alpha-galactosidase A (alpha-Gal A) mutation determined to be amenable by an in vitro assay |
|---|---|
| Physical Description: | 1 PDF file (98 pages) illustrations |